{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:28:32Z","timestamp":1786375712372,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Single-tablet regimens (STRs) are widely used to treat HIV but are often substantially more expensive than multi-tablet regimens (MTRs). Few data exist comparing the effectiveness of STRs compared to contemporary once-daily MTRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We merged data on persons with HIV (PWH) insured through WA State Medicaid in 2023 with statewide, public health HIV RNA surveillance data and used Poisson regression to estimate the relative risk (RR) of viral suppression (HIV RNA &amp;lt;200 copies\/mL) associated with different antiretroviral therapy (ART) regimens. Models adjusted for sex, age, race, ethnicity, time since HIV diagnosis, housing status, healthcare system providing care, region, and receipt of Ryan White services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2599 (90.4%) of 2874 PWH were virally suppressed. In multivariate analysis, lower levels of viral suppression were significantly associated with female sex at birth, younger age, being unstably housed, and use of darunavir-containing MTRs, but not other ART regimens. Viral suppression was lower among persons treated with 2025 US guideline recommended 1st-line MTRs (dolutegravir [DTG] + emtricitabine [FTC]\/tenofovir alafenamide [TAF], DTG + FTC\/tenofovir disoproxil fumarate [TDF], DTG + lamivudine [3TC]) than bictegravir (BIC)\/FTC\/TAF, however, this difference was not significant (88.9% vs 91.6%, RRadj = 0.98, 95% CI 0.94\u20131.01). Viral suppression did not significantly vary between persons on BIC\/FTC\/TAF and 1st-line MTRs among unstably housed persons (78.8% vs 78.2%, RR = 1.00, 95% CI 0.84\u20131.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Differences in viral suppression between contemporary STRs and 1st-line MTRs, if any, are likely small. Factors other than drug efficacy\u2014including cost\u2014should inform decisions to use STRs versus 1st-line MTRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag444","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:43:53Z","timestamp":1784202233000},"source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Single and Multi-Tablet HIV Treatment Regimens Are Associated With Similar Levels of Viral Suppression"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3168","authenticated-orcid":false,"given":"Karen","family":"Yao","sequence":"first","affiliation":[{"name":"Clinical Quality and Care Transformation, Washington State Health Care Authority , Olympia, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Lawson","sequence":"additional","affiliation":[{"name":"Disease Control and Health Statistics, Washington State Department of Health , Olympia, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6815-8448","authenticated-orcid":false,"given":"Ryan","family":"Pistoresi","sequence":"additional","affiliation":[{"name":"Clinical Quality and Care Transformation, Washington State Health Care Authority , Olympia, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Clinical Quality and Care Transformation, Washington State Health Care Authority , Olympia, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-3774","authenticated-orcid":false,"given":"Matthew R","family":"Golden","sequence":"additional","affiliation":[{"name":"Center for AIDS and STD, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"HIV\/STI\/HCV Program, Public Health\u2014Seattle & King County , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026081010364844200_ofag444-B1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/OLQ.0000000000001366","article-title":"Estimated lifetime HIV-related medical costs in the United States","volume":"48","author":"Bingham","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2026081010364844200_ofag444-B2","volume-title":"HIV antiviral drugs","author":"Authority WSHC","year":"2024"},{"key":"2026081010364844200_ofag444-B3","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","volume":"70","author":"Raffi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026081010364844200_ofag444-B4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.therap.2020.12.017","article-title":"Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen","volume":"76","author":"Sutton","year":"2021","journal-title":"Therapie"},{"key":"2026081010364844200_ofag444-B5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170661","article-title":"Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy\u2014results from a large French Multicenter Cohort Study","volume":"12","author":"Cotte","year":"2017","journal-title":"PLoS One"},{"key":"2026081010364844200_ofag444-B6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/09540121.2018.1442554","article-title":"Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naive patients","volume":"30","author":"Hemmige","year":"2018","journal-title":"AIDS Care"},{"key":"2026081010364844200_ofag444-B7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US Medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"2026081010364844200_ofag444-B8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"},{"key":"2026081010364844200_ofag444-B9","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25758","article-title":"Effectiveness and tolerability of dolutegravir and abacavir\/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain","volume":"24","author":"Suarez-Garcia","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2026081010364844200_ofag444-B10","doi-asserted-by":"crossref","DOI":"10.1177\/2325958218822304","article-title":"Desimplification of single tablet antiretroviral (ART) regimens-A practical cost-savings strategy?","volume":"18","author":"Krentz","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2026081010364844200_ofag444-B11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.12998\/wjcc.v7.i14.1814","article-title":"Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: a cohort study","volume":"7","author":"Rossi","year":"2019","journal-title":"World J Clin Cases"},{"key":"2026081010364844200_ofag444-B12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239704","article-title":"De-simplifying single-tablet antiretroviral treatments for cost savings in France: from the patient perspectives to a 6-month follow-up on generics","volume":"15","author":"Giraud","year":"2020","journal-title":"PLoS One"},{"key":"2026081010364844200_ofag444-B13","author":"Adolescents PoAGfAa"},{"key":"2026081010364844200_ofag444-B14","author":"Authority WSHC"},{"key":"2026081010364844200_ofag444-B15","volume-title":"HIV epidemiology report and community profile 2024","author":"County PH-SK","year":"2024"},{"key":"2026081010364844200_ofag444-B16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","article-title":"Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial","volume":"14","author":"Pozniak","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2026081010364844200_ofag444-B17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3947\/ic.2016.48.3.219","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection: a sub-analysis of phase 3 clinical trials","volume":"48","author":"Choi","year":"2016","journal-title":"Infect Chemother"},{"key":"2026081010364844200_ofag444-B18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"Dejesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081010364844200_ofag444-B19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/15284336.2017.1330440","article-title":"Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI","volume":"18","author":"Arribas","year":"2017","journal-title":"HIV Clin Trials"},{"key":"2026081010364844200_ofag444-B20","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"key":"2026081010364844200_ofag444-B21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hiv.13655","article-title":"De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: acceptance, patient-reported outcomes, and cost savings in a multicentre study","volume":"25","author":"Oosterhof","year":"2024","journal-title":"HIV Med"},{"key":"2026081010364844200_ofag444-B22","doi-asserted-by":"crossref","first-page":"S675","DOI":"10.2105\/AJPH.2008.137810","article-title":"The health impact of supportive housing for HIV-positive homeless patients: a randomized controlled trial","volume":"99 Suppl 3","author":"Buchanan","year":"2009","journal-title":"Am J Public Health"},{"key":"2026081010364844200_ofag444-B23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2015.302905","article-title":"Housing Status, medical care, and health outcomes among people living with HIV\/AIDS: a systematic review","volume":"106","author":"Aidala","year":"2016","journal-title":"Am J Public Health"},{"issue":"S4","key":"2026081010364844200_ofag444-B24","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.2105\/AJPH.2018.304689","article-title":"Reducing HIV-related health disparities in the health resources and services Administration's Ryan White HIV\/AIDS program","volume":"108","author":"Mandsager","year":"2018","journal-title":"Am J Public Health"},{"key":"2026081010364844200_ofag444-B25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/OLQ.0000000000002136","article-title":"Budget impact of eliminating Medicaid prior authorizations for antiretrovirals in Washington state","volume":"52","author":"Golden","year":"2025","journal-title":"Sex Transm Dis"},{"key":"2026081010364844200_ofag444-B26","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz294","article-title":"HIV care for patients with Complex needs: a controlled evaluation of a walk-in, incentivized care model","volume":"6","author":"Dombrowski","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026081010364844200_ofag444-B27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/hiv.70025","article-title":"Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: a systematic review and meta-analysis","volume":"26","author":"Barda","year":"2025","journal-title":"HIV Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag444\/70348469\/ofag444.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag444\/70348469\/ofag444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag444\/70348469\/ofag444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:36:57Z","timestamp":1786372617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag444\/8746813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag444","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,29]]},"article-number":"ofag444"}}